Revance Announces Departure of Chief Financial Officer

NEWARK, Calif.--( BUSINESS WIRE)--Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that Lauren Silvernail has resigned as Revance’s Chief Financial Officer and Chief Business Officer, effective as of May 29, 2018, to pursue a Chief Financial Officer role at an aesthetics company in Orange County, California, where she resides.

Her departure is not based on any disagreement with the company’s accounting principles or practices, internal controls or financial statement disclosures.